Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study

Magdy El-Salhy,1,2 Jan Gunnar Hatlebakk,2 Odd Helge Gilja,2 Anja Bråthen Kristoffersen,3 Trygve Hausken2

ABSTRACT
Objective Faecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings.

Design This randomised, double-blind, placebo-controlled study randomised 165 patients with IBS to placebo (own faeces), 30 g FMT or 60 g FMT at a ratio of 1:1:1. The material for FMT was obtained from one healthy, well-characterised donor, frozen and administered via gastroscope. The primary outcome was a reduction in the IBS symptoms at 3 months after FMT (response). A response was defined as a decrease of 50 or more points in the total IBS symptom score. The secondary outcome was a reduction in the dysbiosis index (DI) and a change in the intestinal bacterial profile, analysed by 16S rRNA gene sequencing, at 1 month following FMT.

Results Responses occurred in 23.6%, 76.9% (p<0.0001) and 89.1% (p<0.0001) of the patients who received placebo, 30 g FMT and 60 g FMT, respectively. These were accompanied by significant improvements in fatigue and the quality of life in patients who received FMT. The intestinal bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms.

Conclusions FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose.

Trial registration www.clinicaltrials.gov (NCT03822299) and www.cristin.no (ID657402).

INTRODUCTION
Irritable bowel syndrome (IBS) is a relatively common gastrointestinal disorder with an estimated prevalence of 11.2% in the global population.1 2 Although IBS does not increase mortality, it reduces the quality of life considerably.1 2 The aetiology of IBS is not completely understood, and there is no effective treatment for the condition.1 2 The gut microbiota in patients with IBS differs from that of the healthy subjects, including exhibiting a low bacterial diversity (dysbiosis).1 3–5 It is believed that microbiota dysbiosis is one of the factors contributing to the aetiology of IBS.1

The application of faecal microbiota transplantation (FMT) in several open-label trials with small cohorts of patients with IBS has produced good results.1 One recent randomised double-blind, placebo-controlled study of FMT found positive results for FMT, whereas another found no effect.6 7 The present study was carried out to resolve these contradictory findings.

METHODS
Trial design The patients included in this single-centre, randomised, double-blind, placebo-controlled, parallel-group study were seen twice: at the baseline and 1 month after transplantation. At the
baseline visit, the patients provided a faecal sample and were asked to complete five questionnaires to assess their abdominal symptoms, fatigue and quality of life. At the second visit, the patients provided a faecal sample and completed a new set of questionnaires. The patients also completed similar sets of questionnaires at 2 weeks and 3 months after FMT, and returned them by post. The patients were asked to keep a diary to record bowel habits and register any adverse events. Polyethylene glycol and loperamide were allowed during the intervention as rescue medication. The frequency of using these rescue medications in the three intervention groups was not recorded.

Enrolment and randomisation of patients

Randomisation

The patients were randomised to the placebo (30 g of their own faeces), 30 g FMT and 60 g FMT groups at a ratio of 1:1:1 in blocks of six using a Web-based system (http://www.randomisation.com) by a nurse who was not involved in the trial (figure 1). The patients delivered two faecal samples at the start of the trial to the same nurse: one was used for gut bacterial analysis in all patients, while the other was either used for transplantation (in patients randomised to placebo) or discarded (in patients randomised to ‘superdonor’ FMT, as described later). The researcher who prepared the transplant was not aware of the identity of the faecal sample used for transplantation. The patients and researchers involved in the study were blinded to the randomisation. The randomisation key was revealed to the researcher and patients after the trial had ended.

Patients

Patients who fulfilled the Rome IV criteria for the diagnosis of IBS without red flags were recruited from those attending the outpatient clinic at Stord Hospital. All of the patients had been experiencing IBS symptoms for a long time (mean = 17 years, range = 9–25 years), and the onset of symptoms had not been associated with gastrointestinal or other infections. The medical history was obtained for all patients, and they underwent a complete physical examination as well as blood tests for full blood count, electrolytes and inflammatory markers including faecal calprotectin, liver tests and thyroid function tests. They also underwent a gastroscopy with duodenal biopsies and a colonscopy with segmental biopsies to exclude other gastrointestinal diseases.

The patients had not previously consumed a low-fermentable oligo-, di-, monosaccharides and polyols diet. All of the recruited patients adhered to a diet consistent with the modified guidelines of the National Institute for Health and Care Excellence (NICE) at least for 3 months, which did not result in a marked improvement in symptoms, including in the bowel habit, abdominal pain or abdominal bloating/distension. These patients were considered as non-responders to a NICE-modified diet, and they stopped consuming that diet on entering the trial. They underwent a 12-hour course of IBS treatment lasting 2 days that provided with information delivered by a gastroenterologist, specialist nurse, psychiatrist, dietitian and physiotherapist. The patients’ symptoms improved slightly after participating in the course, which is consistent with previously published data related to a similar course.

The following inclusion criteria were applied:

1. Aged 18–85 years.
2. Moderate-to-severe IBS symptoms, as indicated by a score of ≥ 175 on the IBS Severity Scoring System (IBS-SSS).
3. Presence of systemic disease, immune deficiency or treatment with immune-modulating medication.
4. Pregnant, planning pregnancy or lactating.
5. Having undergone any abdominal surgery, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy.
6. Severe psychiatric disorder, or alcohol or drug abuse.

The exclusion criteria were as follows:

1. Use of probiotics or treatment with antibiotics within 8 weeks prior to study entry.
2. Use of IBS medication within the previous 3 months, with the exception of polyethylene glycol and loperamide.
Donor
A single superdonor was recruited and screened according to the European guidelines for donors for FMT. This involved interviewing him to obtain his medical history and lifestyle habits to exclude any exposure to infectious agents or risky social or sexual behaviour such as drug abuse. He also underwent a physical examination as well as blood tests to exclude gastrointestinal, metabolic or neurological disorders (full blood count, blood glucose, electrolytes and inflammatory markers), liver tests and thyroid function tests. Serology screening tests for HIV, syphilis and hepatitis A, B and C were also performed. Stool culturing was performed for pathogenic bacteria (Shigella spp., Salmonella spp., Campylobacter spp., Yersinia spp. and toxin-producing Clostridoides difficile). Rotavirus and stool ova and parasites were also examined. The findings of all of these tests and examinations were negative.

The donor was an athletic Caucasian male aged 36 years. He was a non-smoker, healthy, not taking any medication and had a BMI of 23.5 kg/m². He was not related to any of the patients in the trial. His mother (a medical professional) confirmed that he was born via a vaginal delivery, breastfed and had been treated three times with antibiotics during his life. He trained for 1 hour five times weekly. The MoBa Food Frequency Questionnaire was used to determine his frequency of consuming 225 food items grouped according to the Norwegian meal patterns over the previous 12 months, and his answers were analysed using software for nutrient calculations. The superdonor’s diet was within the normal range of those of 35 previously examined healthy subjects. However, the superdonor regularly took dietary supplements rich in proteins, vitamins, fibre and minerals (online supplementary table 1) that made his diet richer than average in those substances.

His microbiota in a faecal sample was analysed using the GA-map Dysbiosis Test (Genetic Analysis, Oslo, Norway), which revealed a dysbiosis index (DI) of 1, indicating normobiosis. Despite the donor having a DI of 1, deviation from the expected normal abundance was observed in 14 of the 39 bacteria markers. These deviating bacteria belong to the typical commensal bacteria species, and increases or decreases in their abundances are not considered to contribute to dysbiosis. In all, 12 of the bacteria were in the phylum Firmicutes, with one each in the phyla Proteobacteria and Verrucomicrobia. The other 25 more opportunistic bacteria markers that showed abundances similar to normal are important candidates in a dysbiotic condition (figure 2). The donor had donated his faeces in 18 months, and his faeces samples were tested every 3 months. The samples remained normobiotic, with only minor variations in the constituent bacteria (figure 3).

Faecal sample collection, preparation and administration
Faecal samples from the superdonor and the patients were frozen immediately and kept at −20°C until they were delivered frozen to the laboratory on the same day. They were kept at −80°C in the laboratory, and thawed at 4°C for 2 days before transplantation. On the day of transplantation, the faecal samples were weighed, and 50 g and 60 g portions were mixed with 40 mL of sterile saline (0.9 NaCl), filtered through a 110 cm × 10 cm non-woven swab (One Med, Helsinki, Finland), drawn into 50 mL sterile syringes, sealed and kept at 4°C until the time of transplantation. Each transplant was administered to the distal duodenum via the working channel of a gastroscope, which was then flushed with another 40 mL of sterile saline.

Measures
Abdominal symptoms, fatigue and quality of life
Abdominal symptoms were assessed using the IBS-SSS and the Birmingham IBS Symptom (Birmingham IBS-S) questionnaires. Fatigue was measured using the Fatigue Assessment Scale (FAS). Quality of life was measured using the IBS Quality of Life (IBS-QoL) and Short-Form Nepean Dyspepsia Index (SF-NDI) questionnaires. Higher IBS-QoL and lower SF-NDI scores indicate a better quality of life.

Patients whose total IBS-SSS score decreased by ≥50 points after FMT were considered responders. A decrease of ≥175 points in the IBS-SSS total score, a decrease of ≥4 points in the FAS score and an increase of ≥14 points in the IBS-QoL score were considered to indicate significant clinical improvements.

Figure 2 Although the superdonor was normobiotic, his bacterial profile deviated from the expected normal abundance in 14 of the 39 bacteria markers. The deviating bacteria belong to the typical commensal bacteria species that do not contribute to dysbiosis. In all, 12 of these bacteria belong to the phylum Firmicutes (grey), one to the phylum Proteobacteria (light green) and one to the phylum Verrucomicrobia (light blue).
in abdominal symptoms, fatigue and quality of life, respectively.12 16 18 The responses were also analysed according to the European Medicines Agency and (EMA) and the Food and Drug Administration (FDA) using a composite responder endpoint.19 20 According to EMA, a responder should fulfil the response criteria for at least 50% of the observation time. The response criteria for IBS-D are an improvement at least 30% in the abdominal pain score and a 50% reduction in the number of days with at least one stool that has consistency of 6 or seven as compared with the base line. The response criteria for IBS-C are a reduction at least 30% in the abdominal pain score and an increase of at least one complete spontaneous bowel movement per week as compared with the base line. In IBS-M, a responder is a patient who has at least 30% improvement in the abdominal pain score and a subjects global assessment of efficacy scale of the highest two improvement grades in a 7-point scale, or of the highest improvement grade in a 5-point scale as compared with the base line.

Faecal bacterial analysis

The faecal bacteria were analysed with the GA-map Dysbiosis Test using a method described in detail elsewhere.3 4 In brief, the test uses the 16S rRNA gene to determine both the bacterial profile and DI. It detects bacteria within five phyla (Firmicutes, Proteobacteria, Bacteroidetes, Tenericutes and Verrucomicrobia) that cover 10 bacterial classes, 36 genera and 32 species,3 which means that the test assesses >300 bacteria at different taxonomic levels.4 The DI is measured on a 5-point scale from 1 to 5 (severe dysbiosis), where DI values>2 indicate the presence of dysbiosis.3

The GA-map Dysbiosis Test was also used to analyse the changes in the intestinal bacterial profile following transplantation, in which the bacterial abundance was quantified from –3 to +3, where 0 represents the normal value based on a previous analysis of faecal samples of 297 healthy subjects.3 In addition, principal component analysis (PCA) was used to plot scaled

Figure 3  Scaled principal component analysis plot of faecal samples from the superdonor and patients before transplantation. The patient samples are indicated by small grey circles. The superdonor samples are indicated by the larger circles of different colours that indicate the sampling times: Black, 3 months; red, 6 months; green, 9 months; blue, 12 months; light blue, 15 months; and pink, 18 months. All of the superdonor samples are grouped closely together and remain in very similar positions over time.

Table 1  Characteristics of patients at the trial baseline

| Characteristic                          | Overall     | Placebo   | 30 g FMT | 60 g FMT | P     |
|----------------------------------------|-------------|-----------|----------|----------|-------|
| All patients                           | 164         | 55        | 54       | 55       |       |
| Age, years                             | 39.9±9.0    | 41.2±13.7 | 39.2±12.4| 39.3±13.2| 0.672 |
| Sex, female/male                       | 133/32      | 47/8      | 40/14    | 46/9     | 0.189 |
| IBS-D                                  | 63          | 21        | 22       | 20       |       |
| IBS-C                                  | 62          | 22        | 20       | 20       | 0.989 |
| IBS-M                                  | 39          | 12        | 13       | 14       |       |
| IBS-SSS score                          | 313.4±80.3  | 315.2±77.1| 311.8±76.8| 313.9±87.3| 0.975 |
| Birmingham IBS-S score                 | 24.3±7.1    | 23.2±8.1  | 26.5±6.0 | 25.2±6.8 | 0.050 |
| IBS-Qol score                          | 113.5±21.8  | 117.8±19.7| 109.1±22.7| 113.4±22.4| 0.117 |
| SF-NDI score                           | 30.2±7.7    | 29.9±1.6  | 29.7±1.7 | 30.9±8.4 | 0.728 |
| FAS score                              | 31.1±4.9    | 30.6±4.9  | 31.4±5.1 | 31.3±4.8 | 0.634 |
| DI                                     | 2.8±1.1     | 2.7±1.1   | 2.8±1.0  | 2.9±1.0  | 0.781 |
| Patients with dysbiosis                | (64)        | (67)      | (57)     | (67)     | 0.578 |
| PPI medication                         | 59 (35.8)   | 21 (38.2) | 20 (36.4)| 18 (32.7)| 0.810 |
| Birth-control medication               | 84 (50.9)   | 25 (45.5) | 29 (52.7)| 30 (54.5)| 0.601 |
| Antimigraine medication                | 12 (7.3)    | 3 (5.5)   | 5 (9.1)  | 4 (7.3)  | 0.764 |
| Medication against asthma/allergies    | 18 (10.9)   | 6 (10.9)  | 7 (12.7) | 5 (9.1)  | 0.829 |
| Medication with levoxythroxine         | 3 (1.8)     | 1 (1.8)   | 0 (0)    | 2 (3.6)  | 0.361 |
| Medication with heart/vascular drugs   | 6 (3.6)     | 3 (5.5)   | 2 (3.6)  | 1 (1.8)  | 0.595 |

Data are mean±SD, n, n/n, (%) or n (%) values.

DI, dysbiosis index; FAS, Fatigue Assessment Scale; FMT, faecal microbiota transplantation; IBS, irritable bowel syndrome; IBS-Qol, IBS Quality of Life; IBS-SSS, IBS Severity Scoring System; PPI, proton-pump inhibitor; SF-NDI, Short-Form Nepean Dyspepsia Index.
probe signals inside an ellipse that covered 80% of the samples within a group. The differences in the signals were analysed using the lmFit function in the limma package.21

Outcomes
The primary endpoint was a reduction in the IBS-SSS total score of ≥50 points at 3 months following transplantation,22 which the secondary endpoint was a change in the DI and intestinal bacterial profile.

Ethics
All subjects provided both oral and written consents to participate.

Statistical analysis
Assuming that a placebo effect was 40% and an effect size of β=0.80). We calculated the sample size required in each arm of the trial was calculated by assuming that a placebo effect was 40% and an effect size of β=0.80. We calculated the sample size required in each arm of the trial was calculated by assuming that a placebo effect was 40% and an effect size of β=0.80. We calculated the sample size required in each arm of the trial was calculated by assuming that a placebo effect was 40% and an effect size of β=0.80.

Table 2 IBS-SSS total scores and scores for the four items of the scale in placebo and FMT-treated patients following transplantation

| Time   | Group          | Total score | 1       | 2       | 3       | 4       |
|--------|----------------|-------------|---------|---------|---------|---------|
| 0      | Placebo        | 315.2±77.1  | 107.5±46.1| 55.5±24.7| 76.1±20.7| 75.4±19.8|
|        | 30g FMT        | 311.8±76.8  | 111.1±42.8| 51.0±25.8| 76.4±19.2| 75.6±17.8|
|        | 60g FMT        | 313.3±87.3  | 106.5±45.8| 55.0±25.4| 78.6±18.0| 75.6±20.8|
| 2 weeks| Placebo        | 278.7±124.7 | 88.1±57.0| 51.2±30.5| 62.6±28.5| 64.5±27.5|
|        | 30g FMT        | 244.0±98.5  | 84.4±49.3| 35.0±24.8| 53.3±25.7| 54.4±25.2|
|        | 60g FMT        | 184.6±96.3  | 58.9±41.9| 32.7±26.0| 43.6±26.0| 48.2±26.4|
| 1 month| Placebo        | 299.5±106.1 | 102.0±51.2| 53.5±27.4| 70.3±25.1| 69.1±26.3|
|        | 30g FMT        | 213.4±100.1 | 97.7±47.8| 36.9±22.8| 49.4±28.9| 50.9±29.1|
|        | 60g FMT        | 186.8±107.0 | 66.8±50.8| 33.7±24.6| 40.4±28.4| 46.2±26.8|
| 3 months| Placebo       | 307.0±87.1  | 112.0±69.7| 56.8±31.8| 73.1±22.3| 71.7±22.0|
|        | 30g FMT        | 186.3±109.0 | 69.4±48.5| 30.5±21.7| 44.6±29.7| 45.3±30.9|
|        | 60g FMT        | 168.6±117.9 | 56.5±47.5| 30.4±26.4| 35.6±26.2| 40.2±27.1|

IBS-SSS items: 1, abdominal pain; 2, abdominal distension; 3, dissatisfaction with bowel habits; 4, interference with quality of life.

Data are mean±SD values.
*p<0.05 compared with placebo.
**p<0.01 compared with placebo.
***p<0.001 compared with placebo.
†p<0.05 compared with 30g FMT.
FMT, faecal microbiota transplantation; IBS, irritable bowel syndrome; FMT, faecal microbiota transplantation.
Abdominal symptoms, fatigue and quality of life

Abdominal symptoms as measured using IBS-SSS and Birmingham IBS-S were significantly improved after 3 months for both 30 g FMT and 60 g FMT compared with placebo (table 2 and online supplementary table 3), as was fatigue as assessed using FAS (table 3) and the quality of life as assessed using IBS-QoL and SF-NDI (table 4 and online supplementary table 4). In more detail, there were clinical improvements in abdominal symptoms in 5.5%, 35.2% and 47.3% of the patients in the placebo, 30 g FMT and 60 g FMT groups, respectively, in fatigue in 21.8%, 53.7% and 52.7% of them, and in the quality of life in 7.3%, 61.1% and 58.2% of them (online supplementary table 5). The responses according to EMA/FDA composite responder endpoint, 3 months after FMT were 16.7%, 50% and 70.9% in the placebo, 30 g and 60 g groups, respectively. The responses in 30 g and 60 g groups versus placebo group were significant (p<0.0001, both). There was a significant difference in response between 30 g and 60 g groups (p=0.004).

Bacterial analysis

Some of the tubes containing faecal samples shattered during transportation to the laboratory for analysis, which resulted in the bacterial analyses of faecal samples before and after transplantation only being performed on 47, 42 and 39 patients in the placebo, 30 g FMT and 60 g FMT groups, respectively. The DI values before transplantation were 2.6±1.1, 2.8±1.1 and 2.7±0.9 in the placebo, 30 g FMT and 60 g FMT groups, respectively; the corresponding values after transplantation were 2.6±1.1, 2.6±1.1 and 2.4±1.1 (p=0.087, 0.508 and 0.262). Dysbiosis was present in 57%, 55% and 61% of the patients in the placebo, 30 g FMT and 60 g FMT groups before transplantation, respectively, in 53%, 50% and 39% of them after transplantation (p=0.836, 0.828 and 0.108, respectively).

The analysis of the faecal bacterial profiles obtained using the GA-map Dysbiosis Test showed significant changes in the abundance of bacteria in the 30 g FMT and 60 g FMT groups but not in the placebo group (online supplementary table 6). *Alitipes* spp. were increased for both 30 g FMT and 60 g FMT. *Bacteroides* and *Prevotella* spp. increased in the 30 g FMT group while *Eubacterium hallii* decreased, and *Firmicutes* spp. and *Akkermansia muciniphila* increased in the 60 g FMT group, while *Dorea* spp. decreased.

PCA and the differences in signals analysed using the limFit function in the limma package showed changes in the bacterial profiles after transplantation in the placebo, 30 g FMT and 60 g FMT groups as well as in the responder and non-responder groups (figure 5). The same approach showed that the responders in both the 30 g FMT and 60 g FMT groups had higher signals for *Eubacterium bifforme*, *Lactobacillus* spp. and *Alitipes* spp. after transplantation, and lower signals for *Bacteroides* spp. (online supplementary figure 1). These changes occurred in responders in the 30 g FMT and 60 g FMT groups but not in the placebo group (online supplementary figures 2–5).

The IBS-SSS score was significantly correlated with the concentrations of *Lactobacillus* spp. (p=0.002, r=−0.3) and
Table 5  Adverse events following transplantation in patients with IBS.

| Adverse event                  | Placebo  | FMT total | 30 g FMT | 60 g FMT |
|--------------------------------|----------|-----------|----------|----------|
| Nausea                         | 9 (16.3) | 17 (15.6) | 8 (14.8) | 9 (16.4) |
| Abdominal pain/cramping/ tenderness | 0 (0)    | 21 (19.3)* | 11 (20.4) | 10 (18.2) |
| Diarrhoea                      | 2 (3.6)  | 26 (23.9)* | 14 (25.9) | 12 (21.8) |
| Constipation                   | 1 (1.8)  | 24 (22.0)* | 13 (24.1) | 11 (20)   |
| Diverticulitis                 | 0 (0)    | 2 (1.8)   | 2 (1.8)  | 0 (0)     |

Data are n (%) values.
* p<0.001 compared with placebo.
FMT, faecal microbiota transplantation; IBS, irritable bowel syndrome.

Alistipes spp. (p=0.001, r=−0.3) but not with that of Eubacterium biforme (p=0.754, r=0.03) or Bacteroides spp. (p=0.458, r=0.06). The FAS score was correlated with the concentration of Alistipes spp. (p=0.007, r=−0.2) but not that of Eubacterium biforme (p=0.137, r=0.1), Lactobacillus spp. (p=0.829, r=−0.02) or Bacteroides spp. (p=0.174, r=0.1).

Adverse events

Mild intermittent abdominal pain, diarrhoea or constipation occurred in the first 2 days after FMT (table 5). Two patients (a 52-year-old male and a 55-year-old female) developed diverticulitis at 2 and 3 months after FMT. Both had diverticulosis as verified by colonoscopy and had experienced several diverticulitis attacks before FMT.
DISCUSSION
The findings of this study show that FMT is an effective treatment for IBS that improves both the symptoms and quality of life regardless of the IBS subtype. About half of the patients experienced significant clinical improvements in abdominal symptoms, fatigue and quality of life. These improvements were accompanied by changes in the bacterial faecal profile but not in the DI. The clinical relevance of the dysbiosis has been questioned recently. It is notable that the scores in all IBS-QoL domains except for health worries improved after the patients received FMT. This is probably because the patients attended an IBS course prior to the trial, which is reported to improve the perceived knowledge of IBS. The response to FMT increased with the dose. The adverse events of FMT were mild self-limiting gastrointestinal symptoms. It is noteworthy that a cohort of patients with IBS stated that they would give up an average of 15 years of their life (corresponding to 25% of their remaining lifespan) while 14% would risk a 1-in-1000 chance of death to receive a treatment that would make them free of IBS symptoms.

At 1 month following the FMT, higher concentrations of Eubacterium biforme, Lactobacillus spp. and Alistipes spp. and a lower concentration for Bacteroides spp. were observed in this study in both the 30 g FMT and 60 g FMT groups. The concentrations for Alistipes spp. and Lactobacillus spp. were inversely correlated with the IBS-SSS score, while the signal for Alistipes spp. was inversely correlated with the FAS score. These findings indicate an association between the clinical improvement and the changes found in the bacterial profile following FMT in the present patients.

The finding that frozen faeces samples were effective in FMT confirms previous observations for FMT in Clostridioides difficile in patients with IBS. Furthermore, administering the transplants via the upper gastrointestinal route with the aid of a gastroscope seems to work well. These observations would eliminate the logistical problems associated with both FMT involving fresh faeces and the bowel preparation needed for administering such a transplant to the colon. Moreover, it might be possible to establish faeces banks for the routine clinical use of FMT.

It is difficult to compare the findings of the present study with those of previously reported randomised placebo-controlled trials due to differences in the sizes of the patient cohorts, the forms and amounts of the transplants, the routes of administration and the donors used. Johnsen et al investigated 83 patients with either IBS-D or IBS-M in whom 50–80 g of a mixture of the faeces from two donors was introduced into the colon. Halkjaer et al included 51 patients with all IBS subtypes except unclassified IBS who received 50 g of a mixture of faeces from four donors in a capsule form for 12 days (totalling 600 g). In the present study, the response rate in the placebo group at 2 weeks after transplantation was 49.1%, which decreased to 24.5% after 1 month and 23.6% after 3 months following transplantation. The placebo-group response in this study at 3 months after transplantation was slightly lower than that of 30% reported by Johnsen et al. This difference could be due to the present placebo group containing almost twice as many patients as in that previous study. Moreover, the patients in the study of Johnsen et al were subjected to bowel preparation and colonoscopy, which is often painful and takes more time than the gastroscopy applied in the present study. This aspect could have affected the expectations of the patients and increased the placebo effect. Halkjaer et al used a reduction in the IBS-SSS score as the primary end point rather than a response based on a definition of such a reduction in IBS-SSS score, which makes it difficult to compare the response in their placebo group with the present observations.

The clinical efficacy of FMT is not affected by the choice of the donor in patients with Clostridioides difficile whereas the success of FMT in inflammatory bowel disease and other disorders is donor-dependent. A new definition of superdonor has emerged for someone who is normobiotic and has a positive microbial signature, but an attempt to use stool pooling to produce a superdonor was not successful. Two randomised double-blind, placebo-controlled studies of FMT in patients with IBS produced conflicting results, which might have been due to variability in the donor stools used.

What constitutes a positive microbial signature in an IBS superdonor remains unclear. Therefore, when choosing the superdonor in the present study, we had to consider the factors that might positively affect intestinal microbiota. Smoking/smoking cessation affects the gut microbiota negatively. To be born by caesarean section and/or be formula-fed affect the gut microbiota profile and reduce the bacterial diversity. Frequent treatment with antibiotics and/or a regular intake of non-antibiotic drugs have negative effects on the gut microbiota. Furthermore, the superdonor should not be a first-degree relative of any of the patients in a trial since the intestinal microbiota is affected by the genetic composition, and a superdonor and recipient with greater genetic similarity may also have greater similarities in their faecal microbiota. Thus, among the several candidate donors that we screened, we chose a donor who was a non-smoker, not taking any medication and had been treated only a few times with antibiotics. He was born via a vaginal delivery and breastfed, he trained regularly, consumed a sport-specific diet rich in protein and fibre, and was not related to any of the patients in the trial.

The present study utilised a single well-defined donor who was normobiotic with a bacterial signature that included an abundance of Streptococcus, Dorea, Lactobacillus and Ruminococcus spp. These four genera of bacteria have been reported to constitute favourable bacteria for a donor. Further studies involving well-defined donors are needed to identify their favourable bacterial signatures.

One strength of this clinical trial is that it involved a relatively large cohort of patients with IBS that included three of the IBS subtypes (including IBS-C) and used a single well-defined donor. Furthermore, it confirmed that frozen faeces samples obtained from a donor are effective in FMT, which facilitates their use in the clinic. However, the study also had limitations: it did not investigate the entire intestinal bacterial contents or the long-term effects of FMT, and it did not record the frequency of using rescue medication in the intervention groups. A simultaneous weakness and strength of the study was that it investigated a cohort of patients that had moderate-to-severe IBS symptoms despite adhering to a diet consistent with the modified NICE diet. This is a weakness because the outcome cannot be applied to the entire IBS population, while it is a strength since it showed that FMT succeeded when diet failed.

Acknowledgements The authors thank Christina Casen (clinical director at the laboratory of Genetic Analysis) for fruitful discussions about intestinal microbiota.

Contributors MES designed the study, obtained the funding, administrated the study, recruited the patients, performed FMT, collected, analyzed, and interpreted the data and drafted the manuscript, ABK analysed the bacterial profiles using PCA and critically revised the manuscript for important intellectual content. OHG, JGH and TH contributed to the design of the study, to the analysis and
interpretation of the data, and critically revised the manuscript for important intellectual content.

**Funding** The study was supported by grants from Helse Fonna (grant no. 40415) and Helse Vest (grant no. 192234).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** The study was performed in accordance with the Declaration of Helsinki and was approved by the Regional Committee for Medical and Health Research Ethics West, Bergen, Norway (2017/1197/REK vest).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are stored at Helse Vest server and anonymous data are available upon reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Magdy El-Salhy http://orcid.org/0000-0003-3398-3288

**REFERENCES**

1. El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. *Expert Rev Gastroenterol Hepatol* 2018;12:439–45.

2. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. *World J Gastroenterol* 2012;18:5151–63.

3. Cäsni C, Vebe HC, Sekela J, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. *Aliment Pharmacol Ther* 2015;42:71–83.

4. Eck P, Mazurak N. Dysbiosis in functional bowel disorders. *Ann Nutr Metab* 2018;72:296–306.

5. Wilson BC, Vatanen T, Cutfield WS, et al. The Super-Donor phenomenon in fecal microbiota transplantation. *Front Cell Infect Microbiol* 2019;9:2.

6. Johnsen PH, Hilpisch F, Cavanaugh JP, et al. Fecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. *Lancet Gastroenterol Hepatol* 2018;3:17–24.

7. Halikja S, Christenssen AH, Lo BZS, et al. Fecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. *Gut* 2018;67:2107–15.

8. Eswaran SL, Chey WD, Han-Markey T, et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. *Am J Gastroenterol* 2016;111:1824–32.

9. Ringström G, Storsrud S, Lundqvist S, et al. Development of an educational intervention for patients with irritable bowel syndrome (IBS) – a pilot study. *BMC Gastroenterol* 2009;9:10.

10. Camarana G, Ianiro G, filh E, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* 2017;66:569–80.

11. Ostgaard H, Haasen K, Gudnerson D, et al. Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome. *Moh Med Rep* 2012;5:1382–90.

12. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther* 1997;11:395–402.

13. Roelke AK, Roberts UM, Wilson S. Evaluation of the Birmingham IBS symptom questionnaire. *BMC Gastroenterol* 2008;8:30.

14. Hendriks C, Drent M, Efferich M, et al. The fatigue assessment scale: quality and availability in sarcoidosis and other diseases. *Cure Oral Pulm Med* 2018;24:495–503.

15. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-GQL: a disease-specific quality-of-life questionnaire. *Am J Gastroenterol* 2000;95:999–1007.

16. Wong RKM, Drossman DA. Quality of life measures in irritable bowel syndrome. *Expert Rev Gastroenterol Hepatol* 2010;4:277–84.

17. Arslan G, Lind R, Olafsson S, et al. Quality of life in patients with subjective food hypersensitivity: applicability of the 10-item short form of the Nepean dyspepsia index. *Dig Dis Sci* 2004;49:680–7.

18. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. *Eur Respir J* 2012;40:255–63.

19. Agency EM. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. 2014. Available: https://www.europa.eu/en/documents/scientific-guideline-guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf

20. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry:irritable bowel syndrome-clinical evaluation of drugs for treatment, 2012. Available: http://www.fdagov/downloads/DrgGuidances/UCM205269pdf

21. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 2015;43:e47.

22. Bennett SMP, Böhn L, Storruds S, et al. Multivariate modeling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. *Gut* 2018;67:872–81.

23. Lloyd-Price J, Mahurkar A, Rahnavard G, et al. Erratum: strains, functions and dynamics in the expanded human microbiome project. *Nature* 2017;551:256.

24. Drossman DA, Morris CB, Schnee S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. *J Clin Gastroenterol* 2009;43:541–50.

25. Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection. *JAMA* 2016;315:142–9.

26. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. *Am J Gastroenterol* 2013;108:300–8.

27. Capurso G, Lahiere E. The interaction between smoking, alcohol and the gut microbiome. *Best Pract Res Clin Gastroenterol* 2017;31:579–88.

28. Biedermann L, Brüsslauer K, Zeitz J, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using fish. *Inflamm Bowel Dis* 2020;14:196–501.

29. Korpela K, Dikareva E, Hanski E, et al. Cohort profile: Finnish health and early life microbiota (HELMI) longitudinal birth cohort. *BMI Open* 2019;9:e28500.

30. Yeung OK, Ng YF, Chiu J, et al. A pilot study to determine the gut microbiota of Hong Kong infants fed with breast-milk and/or infant formula (P11-101-19). *Curr Dev Nutr* 2019,3.

31. Jakobsen BS, Abrahamsson TR, Jenmalm MC, et al. Decreased gut microbiota diversity, delayed Bacteroides colonisation and reduced Th1 responses in infants delivered by caesarean section. *Gut* 2014;63:559–66.

32. Rutayisire E, Huang K, Liu Y, et al. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants life: a systematic review. *BMJ Gastroenterol* 2016;16:86.

33. Ianirio G, Filh H, Gabbarini A. Antibiotics as deep modulators of gut microbiota: between good and evil. *Gut* 2016;65:1906–15.

34. Modi SR, Collins JJ, Reina MA. Antibiotics and the gut microbiota. *J Clin Invest* 2014;124:4212–8.

35. Maier L, Pruteanu M, Kahn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. *Nature* 2018;555:623–8.

36. Mustaara N, Burke L, Vlahovich N, et al. The effects of dietary pattern during intensified training on stool microbiota of elite race walkers. *Nutrients* 2019;11:261.

37. Dalton A, Mermier C, Zühl M. Exercise influence on the microbiome–gut–brain axis. *Gut Microbes* 2019;10:555–68.

38. Motiani K, Collado MC, Eskelinen J-J, et al. Exercise training modulates gut microbiota profile and improves endotoxemia. *Med Sci Sport Exer* 2019;doi:10.1249/MSS.0000000000002212. [Epub ahead of print: 16 Aug 2019].

39. Pinn DM, Aronndics OC, Brandt LT. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? *Neuropsych Gastroenterol Motil* 2015;27:19–29.

40. Pinn DM, Aronndics OC, Brandt LT. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. *Am J Gastroenterol* 2014;109:1831–2.

41. Bull MJ, Pummer NT. Part 2: treatments for chronic gastrointestinal disease and gut dysbiosis. *Integr Med* 2015;14:25–33.

42. Holvoet T, Joossens M, Wang J, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. *Gut* 2017;66:380–2.

43. Chong C, Bloomfield F, D’Sullivan J. Factors affecting gastrointestinal microbiome development in neonates. *Nutrients* 2018;10:274.